Targeting the Microenvironment in MDS: The Final Frontier

Targeting the Microenvironment in MDS: The Final Frontier

Myelodysplastic syndromes (MDS) are a heterogeneous group of malignant disorders of hematopoietic stem and progenitor cells (HSPC), mainly characterized by ineffective hematopoiesis leading to peripheral cytopenias and progressive bone marrow failure. While clonal dominance is nearly universal at di...

Full description

Bibliographic Details
Main Authors: Patric Teodorescu, Sergiu Pasca, Delia Dima, Ciprian Tomuleasa, Gabriel Ghiaur
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-07-01
Series:Frontiers in Pharmacology
Subjects:
myelodyslastic syndromes
microenvironment
azacytidine
lenalidomide
luspatercept
rigosertib
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2020.01044/full

Similar Items

Similar Items